SubHero Banner

Padcev™ (enfortumab vedotin-ejfv) – New drug approval

December 18, 2019 - The FDA announced the approval of Seattle Genetics’ and Astellas Pharma’s Padcev (enfortumab vedotin-ejfv), for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

Download PDF